In another study, the combination of sorafenib with standard 7 + 3 chemotherapy in elderly patients (aged > 60 years) with AML did not significantly improve survival [66], with similar results seen in a subgroup analysis of patients with FLT3-ITD-mutated AML [66]. Here, FLT3 is linked to acute myeloid leukemia.